JNJ-7706621
Cat. No.：YN270052
CAS No. ：443797-96-4
| 产品名称: | JNJ-7706621 |
| CAS No.: | 443797-96-4 |
| Chemical Name: | 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide |
| Synonyms: | JNJ 7706621 |
| 分子量: | 394.36 |
| 分子式: | C₁₅H₁₂F₂N₆O₃S |
| SMILES: | O=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | JNJ-7706621 是一种有效的aurora kinase抑制剂，同时能有效抑制CDK1和CDK2，对CDK1，CDK2，aurora-A和aurora-B的IC50值分别为 9 nM，3 nM，11 nM 和 15 nM。 |
| IC50和靶点: | [{name:"CDK6/cyclinD1:175 nM (IC50)"},{name: "CDK2/cyclinE:3 nM (IC50)"},{name: "Cdk4/cyclin D1:253 nM (IC50)"},{name: "Cdk1/cyclin B:9 nM (IC50)"},{name: "cdk2/cyclin A:4 nM (IC50)"},{name: "CDK3/Cyclin E:58 nM (IC50)"},{name: "Aurora A:11 nM (IC50)"},{name: "Aurora B:15 nM (IC50)"},{name: "VEGF-R2:154 nM (IC50)"},{name: "VEGF-R1:6400 nM (IC50)"},{name: "VEGF-R3:735 nM (IC50)"},{name: "FGF-R1:575 nM (IC50)"},{name: "FGF-R2:226 nM (IC50)"},{name: "GSK3β:254 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Emanuel, S., Rugg, C.A., Gruninger, R.H., et al.The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinasesCancer Res.65(19),9038-9046(2005)
Seamon, J.A., Rugg, C.A., Emanuel, S., et al.Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitorMol. Cancer Ther.5(10),2459-2467(2006)
